Compare Kohl's Corporation (KSS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Novo Nordisk A/S — how do they compare? Kohl's Corporation trades at $17.33 (market cap $1.99B), while Novo Nordisk A/S trades at $49.52 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 110.8× Kohl's Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| KSS | NVO | |
|---|---|---|
Market Cap | $1.99B | $220.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $71.70 |
52-Week Low | $10.42 | $35.29 |
Enterprise Value | $8.10B | $239.49B |
Dividend Yield | 2.85% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $17.59, up 1.68% on the day, with a bullish technical signal from moving averages. The stock shows deep value metrics with a P/E of 7.27 and P/B of 0.49, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal operational improvements. Cash flow turned positive in 2026 projections at $276M, and the company is focusing on proprietary brands and value initiatives to drive traffic.
Outlook: Turnaround efforts under CEO Michael Bender show early progress, but revenue declines persist. Investment case hinges on margin expansion and market share recovery. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analyst consensus is mixed with a $16.75 price target below current levels, suggesting cautious optimism amid execution uncertainty.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
